SLNO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 Ready to Announce with Confidence?

SLNO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 Ready to Announce with Confidence? Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - April 7, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO) and reminds investors of the May 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the Soleno Phase 3 clinical trial program for DCCR had systematically downplayed, misrepresented, and/or concealed significant evidence of safety concerns potentially related to the administration of DCCR, including issues related to excess fluid retention in clinical trial participants; (2) as a result, the administration of DCCR to treat hyperphagia in individuals with PWS posed materially greater safety risks than disclosed by Soleno or its executives; and (3) consequently, DCCR had materially lower commercial viability and undisclosed risks related to the likelihood of significant and widespread adverse events after its commercial launch, including risks related to patient discontinuation rates, lower patient adoption, prescriber reluctance, adverse regulatory action, and potential reputational and legal fallout.

On August 15, 2025, Scorpion Capital LLC published a report critical of Soleno Therapeutics, Inc., its drug candidate DCCR, and the company's Phase 3 clinical trial program. The report alleged significant concerns regarding the drug's safety, efficacy, and clinical trial data. On this news, the price of Soleno common stock declined from a high of more than $77 per share on August 14, 2025 to close at approximately $68 per share on August 18, 2025, a decline of nearly 12% over two trading days.

Subsequently, on September 10, 2025, Soleno filed a Form 8-K with the U.S. Securities and Exchange Commission disclosing that a patient had died after taking DCCR.On this news, the price of Soleno common stock declined from more than $70 per share on September 9, 2025 to close at approximately $57 per share on September 11, 2025, a decline of approximately 19% over two trading days.

Lastly, on November 4, 2025, Soleno reported its financial results for the third quarter ended September 30, 2025, revealing that the earlier Scorpion Capital report had disrupted the launch trajectory of DCCR and raised concerns within the Prader-Willi syndrome community, resulting in fewer patient start forms and increased discontinuations. On this news, the price of Soleno common stock declined from nearly $64 per share on November 4, 2025 to close at approximately $47 per share on November 5, 2025, a one-day decline of approximately 27%.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Soleno's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Soleno Therapeutics class action, go to www.faruqilaw.com/SLNO or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/291331

Source: Faruqi & Faruqi LLP

Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for Faruqi & Faruqi LLP or all companies in the Banking / Financial Services industry.

SLNO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026

2026-04-07 10:04 AM EDT

QURE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026

2026-04-06 10:40 AM EDT

TCOM DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Trip.com Group (TCOM) Investors of Securities Class Action Deadline on May 11, 2026

2026-04-06 10:14 AM EDT

Dec 16, 2025

What makes a press release rise above the rest? We analyzed the most successful press releases of 2025 to see what caught attention and why. This year’s review looks at total views from human readers and AI systems across the top five hundred public company press releases distributed through TMX Newsfile in 2025. These views come from all of Newsfile’s general distribution channels, such as Yahoo and Apple. They reflect how audiences discovered and engaged with each announcement. Key Insights...

Litigation and Regulation

Banking / Financial Services